文献速递中毒与环境急症呼吸衰竭与机械通气

丁丙诺啡口服暴露后呼吸抑制:美国国家毒物数据库2003-2019年分析

Respiratory depression following medications for opioid use disorder (MOUD)-approved buprenorphine product oral exposures; National Poison Database System 2003-2019.
PubMed 文献 · Clin Toxicol (Phila) · 2020-09-07
一句话结论2003至2019年,丁丙诺啡口服暴露报告病例增加65倍,成人和儿童呼吸抑制发生率约11%,严重结局和死亡也逐年增加。

该研究检索美国国家毒物数据库2003年1月1日至2019年12月31日所有获批用于阿片类使用障碍的丁丙诺啡产品暴露,分析口服暴露后呼吸抑制、插管、纳洛酮使用及临床结局。共纳入27,275例口服暴露(多物质11,010例,单物质16,265例)并随访至已知结局。研究期间报告病例增加65倍,严重结局频率逐年稳定上升;呼吸抑制发生率分别为儿童单物质11.8%、儿童多物质11.2%、成人单物质11.3%、成人多物质11.9%。口服暴露增加显著,成人和儿童严重结局包括死亡均增加。

要点

  • 2003至2019年,丁丙诺啡口服暴露报告病例增加65倍,严重结局频率逐年稳定上升。
  • 儿童单物质口服暴露呼吸抑制发生率为11.8%,儿童多物质为11.2%。
  • 成人单物质口服暴露呼吸抑制发生率为11.3%,成人多物质为11.9%。
  • 口服暴露中,同时摄入一种其他物质时最常见为苯二氮䓬类、阿片类、乙醇和安非他命类。
  • 成人和儿童单物质及多物质口服暴露均出现具有临床意义的呼吸抑制发生率。

适用人群与场景

  • 美国国家毒物数据库2003年1月1日至2019年12月31日报告的获批用于阿片类使用障碍的丁丙诺啡产品口服暴露者,包括成人和儿童,单物质和多物质暴露,均随访至已知结局。

诊断标准与关键阈值

  • 呼吸抑制定义为记录的「相关」呼吸抑制:呼吸频率<10次/分和/或脉搏血氧饱和度(SpO2)≤90%。

研究设计与关键结果

  • 研究类型为美国国家毒物数据库查询分析,共纳入27,275例丁丙诺啡口服暴露并随访至已知结局,其中多物质暴露11,010例,单物质暴露16,265例。
  • 研究期间报告病例增加65倍,严重结局频率逐年稳定上升。
  • 呼吸抑制发生率:儿童单物质11.8%,儿童多物质11.2%,成人单物质11.3%,成人多物质11.9%。
  • 口服暴露中同时摄入一种其他物质时,最常见为苯二氮䓬类、阿片类、乙醇和安非他命类。
  • 成人和儿童口服暴露后严重结局包括死亡在研究期间均增加。

证据类型、等级与局限

  • 证据类型:基于美国国家毒物数据库的回顾性数据库分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 成人和儿童单物质及多物质丁丙诺啡口服暴露后均可出现具有临床意义的呼吸抑制,发生率约11%,应关注气道和呼吸监测。
  • 口服暴露报告病例及严重结局包括死亡在2003至2019年间增加,提示需重视该类暴露的评估与随访。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Medications for opioid use disorder (MOUD) including buprenorphine is recommended for patients with opioid use disorders. We sought to evaluate the frequencies of respiratory depression, intubation, and naloxone administration, and clinical outcomes among patients reported to the National Poison Database System (NPDS) following single-substance and multiple-substance buprenorphine oral exposures.

METHODS: NPDS was queried for all MOUD-approved buprenorphine product exposures between 1 January 2003 and 31 December 2019. Data abstracted included year, route, gender, age, site of exposure, management site, medical outcome, recorded "related" respiratory depression ("respiratory rate <10 breaths/min and/or a SpO2 (pulse oximetry)≤90%), reported administration of naloxone and intubation in oral exposure cases followed to known outcome. Concomitant products were also recorded in multiple-substance buprenorphine cases.

RESULTS: 27,275 (11,010 multiple and 16,265 single) buprenorphine oral exposures were identified and followed to known outcome. A 65-fold increase in reported cases was reported over the study interval. A steady increase in the frequency of more serious outcomes by year was also observed. Respiratory depression occurred at a frequency of 11.8% (pediatric single-substance), 11.2% (pediatric multiple-substance), 11.3% (adult single-substance), and 11.9% (adult multiple-substance). Among oral exposures of buprenorphine and only one other product, benzodiazepines, opioids, ethanol, and amphetamines were most common.

CONCLUSIONS: Oral exposures have increased substantially between 2003 and 2019. More serious outcomes including deaths following oral exposures to buprenorphine have also increased over the same interval for both adult and pediatric patients. Clinically significant rates of respiratory depression in both adult and pediatric patients when taken alone and with additional substances were observed.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Darracq MA, Thornton SL. Respiratory depression following medications for opioid use disorder (MOUD)-approved buprenorphine product oral exposures; National Poison Database System 2003-2019. Clin Toxicol (Phila). 2020. PMID: 32894033. doi:10.1080/15563650.2020.1814318

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。